U.S. Markets open in 4 hrs 7 mins
  • S&P Futures

    4,464.33
    -9.92 (-0.22%)
     
  • Dow Futures

    34,696.80
    -52.20 (-0.15%)
     
  • Nasdaq Futures

    15,486.67
    -31.08 (-0.20%)
     
  • Russell 2000 Futures

    2,241.04
    +7.84 (+0.35%)
     
  • Crude Oil

    70.60
    -1.37 (-1.90%)
     
  • Gold

    1,757.90
    +6.50 (+0.37%)
     
  • Silver

    22.38
    +0.08 (+0.36%)
     
  • EUR/USD

    1.1708
    -0.0023 (-0.1990%)
     
  • 10-Yr Bond

    1.3700
    0.0000 (0.00%)
     
  • Vix

    25.07
    +6.38 (+34.14%)
     
  • GBP/USD

    1.3678
    -0.0059 (-0.4322%)
     
  • USD/JPY

    109.6840
    -0.2110 (-0.1920%)
     
  • BTC-USD

    45,129.30
    -2,979.29 (-6.19%)
     
  • CMC Crypto 200

    1,127.89
    -97.64 (-7.97%)
     
  • FTSE 100

    6,855.01
    -108.63 (-1.56%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

ZY ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Zymergen Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - September 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zymergen Inc. (NASDAQ: ZY) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.
Lead Plaintiff Deadline: October 4, 2021
No obligation or cost to you.

Learn more about your recoverable losses in ZY: https://www.kleinstocklaw.com/pslra-1/zymergen-inc-loss-submission-form?id=19625&from=5.

Zymergen Inc. NEWS - ZY NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Zymergen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Zymergen you have until October 4, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Zymergen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the ZY lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96656.